Drug-Eluting Stents Will Be Model For CMS/FDA Cooperation – McClellan
Executive Summary
The drug-eluting stent approval and reimbursement process should serve as a model for how CMS and FDA can work more closely together to ensure coverage for new technologies, CMS Administrator Mark McClellan told the Food & Drug Law Institute conference in Washington, D.C. April 15
You may also be interested in...
CMS Innovation Council To Examine Pharmacogenomic Product Coverage
The Centers for Medicare & Medicaid Services' Council for Technology & Innovation will consider coverage of pharmacogenomic products
CMS Innovation Council To Examine Pharmacogenomic Product Coverage
The Centers for Medicare & Medicaid Services' Council for Technology & Innovation will consider coverage of pharmacogenomic products
Medicare Implements AWP-5% Payment Rate For “Uncoded” Drugs
The Centers for Medicare & Medicaid Services is implementing a provision of the 2003 Medicare law that establishes an AWP-5% payment rate for drugs covered by the Outpatient Prospective Payment System that have not yet received a reimbursement code